Multiple Myeloma (MM) research is at the forefront of personalized medicine, driven by rapid advancements in laboratory genomics and molecular diagnostics.

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71% reduction in the risk of disease progression or death compared with those ...

Carol Meyers, 72, knew exactly how her daughter was feeling. Her daughter, Carley Yelyashov, 44, was in the hospital in June 2024 for a stem cell transplant, when healthy stem cells are infused into ...

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Institute for Cell Therapy Discovery & Innovation, The University of ...

1 Department of Neurology, Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China 2 The Second Clinical Medical College, Binzhou Medical University, Yantai, China Multiple myeloma (MM) ...